Editor-in-Chief: Rui-Hua Xu
Sun Yat-sen University Cancer Center
Cancer Communications is a platform for collaboration on basic, clinical, and translational cancer research. Proudly open access - every issue is accessible to the world.
Our oncology journal welcomes submissions spanning clinical trials, epidemiology, molecular and cellular biology, and genetics.
On the Cover
Featured Information
Articles
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms
-  1 November 2024
Tumor derived cell‐free nucleic acid upregulates programmed death‐ligand 1 expression in neutrophil via intracellular Toll‐like receptor signaling
-  30 October 2024
Wnt/GSK‐3β mediates posttranslational modifications of FLYWCH1 to regulate intestinal epithelial function and tumorigenesis in the colon
-  30 October 2024
Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill
-  25 October 2024
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma
-  24 October 2024
Elevated neutrophil extracellular traps by HBV‐mediated S100A9‐TLR4/RAGE‐ROS cascade facilitate the growth and metastasis of hepatocellular carcinoma
- Cancer Communications
-  225-245
-  8 November 2022
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
- Cancer Communications
-  3-41
-  24 November 2022
Tumor microenvironment signaling and therapeutics in cancer progression
- Cancer Communications
-  525-561
-  2 April 2023
METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression
- Cancer Communications
-  338-364
-  5 January 2023
Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
- Cancer Communications
-  297-337
-  10 November 2022
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
- Cancer Communications
-  455-479
-  14 March 2023
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
- Cancer Communications
-  1314-1330
-  6 November 2022
Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?
- Cancer Communications
-  75-86
-  17 November 2022